Leaflet LYTGOBI 4mg film-coated tablets
Indicated for: cholangiocarcinoma
Route of administration: oral
Substance: futibatinib (tyrosine kinase inhibitor)
ATC: L01EN04 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid grapefruit and grapefruit juice.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
This medicine may increase the risk of heart rhythm disturbances.
Futibatinib is a medication used to treat certain cancers, particularly cholangiocarcinoma (bile duct cancer), in patients with an FGFR2 gene mutation. It works by blocking FGFR receptors, which are involved in the uncontrolled growth of cancer cells.
The drug is taken orally as tablets, and the dose is determined by the doctor based on the patient's condition and the stage of the disease. Treatment is ongoing and requires regular medical assessments to monitor its effectiveness and safety.
Common side effects include nausea, dry mouth, diarrhea, fatigue, and changes in blood phosphate levels. In some cases, eye or liver problems may occur, so regular check-ups, including ophthalmological evaluations, are recommended.
Futibatinib provides a valuable option for patients with rare and hard-to-treat cancers, but its use must be closely monitored by healthcare professionals to prevent and manage possible complications.
General data about LYTGOBI 4mg
- Substance: futibatinib
- Date of latest medicines list: 01-06-2026
- Product code: W71199001
- Concentration: 4mg
- Pharmaceutical form: film-coated tablets
- Quantity: 35
- Product type: Generic medicine
- Price: 14721.95 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.